Full Press Release Details
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development.
CRSP
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
Key Takeaway: CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
Price reaction · baseline $46.41 (2022-12-16 close) · clean, no other CRSP news in the window
day 0 close · peak
-5.1%
day 1
-4.5%
day 3
-0.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension